Skip to main content

Table 1 Subject characteristics

From: Treatment effects of stimulant medication in young boys with fragile X syndrome

Age (years) IQ Medication Dose CBCL T score % Time attending % Time out of seat
DSM-ADHD Attention problems On medication Off medication On medication Off medication
5 76 Methylphenidate 0.10 mg/kg A.M. 58 66a 64 80 84 57
6 76 Methylphenidate 0.10 mg/kg A.M. 69a 75b 92 57 35 8
6 73 Dextroamphetamine 0.025 mg/kg A.M. 50 53 68 59 1 0
7 54 Methylphenidate 0.10 mg/kg A.M. 58 64 98 58 0 37
8 48 Methylphenidate 0.05 mg/kg A.M. 56 57 85 73 0 0
9 68 Methylphenidate 0.15 mg/kg A.M. 58 67a 92 92 42 17
9 60 Dextroamphetamine 0.30 mg/kg A.M. 58 66a 85 96 1 2
9 48 Dextroamphetamine 0.10 mg/kg A.M. 51 55 88 80 0 0
10 42 Methylphenidate 0.20 mg/kg A.M. 50 57 87 58 <1 0
10 52 Methylphenidate 0.45 mg/kg daily 60 71b 55 38 0 0
10 44 Dextroamphetamine Dailyc 66a 66a 93 69 2 32
11 42 Methylphenidate 0.25 mg/kg A.M. 62 67a 91 93 0 11
  1. CBCL T scores ranges: normal (<65)
  2. aBorderline (65–69), CBCL T scores range
  3. bClinical (>69), CBCL T scores range
  4. cDosage for one participant was missing due to incomplete parent report